Further to our email notification to all attendees on the 26th of March we can confirm that BOS Basel 2020 will be rescheduled, and new dates are as follows: BOS Basel 2021, 29th and 30th of June, Congress Centre Basel.

This decision is in response to the unprecedented global situation presented by Covid 19. We would like to thank all stakeholders for their support. Stay safe and we look forward to working with you to return with a stellar BOS Basel 2021.

Our BOS Basel 2021 website is now live: click here to view it now.

Welcome

...to Biotech Outsourcing Strategies Basel 2020

Launched in 2006 by Bio2Business Ltd, the Biotech Outsourcing Strategies Events bring together stakeholders in R&D outsourcing to share experience, build existing outsourcing partnerships and forge new buyer/supplier business relationships. The established BOS Formula is built on 4 key pillars; Exhibition showcasing international CROs and CMOs; High Quality Content (delivered through the multi-stream programme); 1-to-1 Partnering; Informal Networking (BOS Events are known for being friendly, intimate events, which create the perfect conditions for networking!).

Since 2016 we are pleased to call Basel our home of our summer event (we run a sister event in Manchester, UK, in November 2020). Located in the heart of Europe, Basel is a unique Life Science Ecosystem which we are proud to support. BOS Basel 2020 will cover Discovery Outsourcing, Small Molecule CMC Outsourcing and Biologics CMC Outsourcing.

Featured Speaker

Outsourcing Antibody and Antibody-Drug-Conjugates Development and Manufacturing: When, Who, and How?

, Senior Director, Head Medicinal Chemistry, IMED RIA, AstraZeneca

ABSTRACT: Outsourcing partnerships for CMC development and manufacturing of biologics are of strategic importance for many companies esp. with innovative pipelines and employing new technologies. Antibody-drug conjugates (ADCs), linking small molecule highly potent drugs to antibodies for efficacy and targeting, offer new treatment options esp. in oncology, while the complexity of ADCs makes their CMC development and manufacturing challenging. Especially in determining its clinical as well as commercial manufacturing set-up, companies must consider what best suits their needs and decide between building... Click here to Read More